It's Not What You Say But How You Say It: Targeting RNA Methylation in AML

Sarah Naomi Olsen; Scott A Armstrong

doi:10.1016/j.molcel.2020.05.027

It's Not What You Say But How You Say It: Targeting RNA Methylation in AML

Mol Cell. 2020 Jun 18;78(6):996-998. doi: 10.1016/j.molcel.2020.05.027.

Authors

Sarah Naomi Olsen¹, Scott A Armstrong²

Affiliations

¹ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: scott_armstrong@dfci.harvard.edu.

PMID: 32559428
DOI: 10.1016/j.molcel.2020.05.027

Abstract

In this month's issue of Cancer Cell, Su et al. (2020) describe two small-molecule inhibitors of the RNA demethylase FTO that demonstrate significant anti-tumor effects in various models of acute myeloid leukemia.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Alpha-Ketoglutarate-Dependent Dioxygenase FTO
Humans
Immune Evasion*
Leukemia, Myeloid, Acute*
Methylation
Neoplastic Stem Cells
RNA

Substances

RNA
Alpha-Ketoglutarate-Dependent Dioxygenase FTO
FTO protein, human

Grants and funding

P01 CA066996/CA/NCI NIH HHS/United States